Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.

Slides:



Advertisements
Similar presentations
HPV Testing and Genotyping
Advertisements

Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University.
Cervical Screening and HPV testing
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Cervical Cancer. Dr. Swapna Chaudhary M.S. (MUM) Consultant Obstetrician & Gynaecologist Infertility Specialist.
Updates on Pap Smear Guidelines 2014
Speaker: Decca Mohammed, MD.  Statistics for cervical cancer and HPV  Association of HPV to cervical cancer, and other cancers  Prevention  Screening.
Treatment Options for CIN Cervical Cancer screening is designed to detect CIN If CIN is present treatment should theoretically avoid subsequent cancer.
Manitoba Cervical Cancer Screening Program April 2010.
Cervix Dr. Raid Jastania. Cervical Cancer Screening HPV infection Pre- Cancerous Dysplasia Cancer years.
Cervical Cancer Cervical dysplasia Cervical cancer Causes Risk factors
Benign Conditions Of The Cervix Dr. Abdalla H. Elsadig MD.
HPV and cervical screening Test of cure
Screening for Cervical Cancer
Management of Women with CIN 1 or LSIL
Spotlight on Cervical Cancer Screening
HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA Roger J Rand.
Benign and premalignant disease of the cervix
Cervical Cancer: Prevention and Treatment
Jacqueline Castagno, MD FACOG Division of Gynecologic Oncology Department of Obstetrics and Gynecology University of Florida College of Medicine.
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Clinical Uses of HPV DNA Testing
Case Presentations: Pre-Invasive Cervical Neoplasia
COLPOSCOPY Cervical Screening QARC Training School October 2012.
HPV: How to prevent your patients from becoming my patients Katina Robison, MD Assistant Professor, Department of Obstetrics & Gynecology Director of Colposcopy.
Cervical Cancer Screening
HPV and Cervical Cancer Screening and Prevention.
Screening Tests for Brest & Cervical Cancer
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
Screening for Cervical Cancer by Visual Inspection Techniques Dr Aruna Batra VMMC & SJH.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Cervical Cancer in California Janet Bates, MD MPH Research Program Director Research and Surveillance Program California Cancer Registry.
Women’s First Health Center Drs. Sylvester, Youngren, Lo and Sansobrino What You Should Know About Cervical Cancer: Part one in a series of four updates.
What Is HPV? Human Papillomaviruses have an icosahedral shape, contain DNA, and are non-enveloped There are at least 100 different types of HPV Over 30.
Cervical Cancer Screening Recommendations 2012, FDA Panel 2014.
Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Screening.
In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.
Cervical Intraepithelial Neoplasm
Top Pap smear Questions. 1-When should Pap screening begin? Age 21 y/o,3yrs after first intercourse.
Adult Medical-Surgical Nursing
Human Papillomavirus (HPV). Wed, Nov Tanjung Jaya, Indonesia.
Premalignant lesions of the cervix. Applied anatomy.
Screening of genital cancers Evidence Based Presented by Dr\ Heba Nour.
CERVICAL SCREENING ANGELIKA KAUFMANN, ST4, UHCW, MEDICAL STUDENT INDUCTION, 2015.
NHS Cervical Screening Programme Introducing HPV triage and test of cure.
2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.
WACCPP rolling PowerPoint. INSTRUCTIONS  This PowerPoint presentation has been designed for use as a rolling backdrop at presentations or events  Before.
HPV-related anogenital cancers
Cytopathology Feb
Cervical Cancer Screening NURS 541: Women’s Healthcare – Diagnosis and Management.
THE NEW CERVICAL CANCER SCREENING PROGRAM
NHS Cervical Screening Programme Introducing HPV Triage
INTRODUCTION: CERVICAL CANCER SCREENING
Cervical Cancer in California
Cervical Cancer Colposcopy & Treatment
Dr N Shailaja Dr Pradeep
Colposcopy triage. Satisfactory colposcopy is defined as complete visualization of the squamocolumnar epithelium, which comprises the cervical region most.
Updates on Pap Smear Guidelines 2014
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Performance Measures Related to Colposcopy for Canadian Cervical Cancer Screening Programs: Identifying Areas for Improvement  Kathleen M. Decker, PhD,
Figure 1: Guidelines for primary cytology# screening in South Africa
SH-sheikhhasani Gyn-oncologist
HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA
Presentation transcript:

Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015

Cervical Cytology n As a screening test for Ca Cx this test has only ~75% sensitivity n Better at detecting Cervical Intraepithelial Ca (CIN) » but then specificity is a problem n Must sample the squamocolumnar junction n More significant if +ve in a high risk individual » Older » Early sex, multiple partners, other STDs » Smoking » HPV infection with high risk subtype n Liquid-based cytology can enhance sensitivity by ≈5% n Start at age 20 or within 3 years first coitus

Cytological Terms n LGEA = Low grade epithelial abnormality »Mostly due to HPV »Also called low grade squamous intraepithelial lesion or LSIL n HGEA = High grade epithelial abnormality »Arises from CIN1 & CIN2 (but these are histological terms) »Also called high grade squamous intraepithelial lesion or HSIL n Both the above have “Possible” variants »That is “Possible LGEA” and “Possible HGEA”

Colposcopy n Limited by need for expert and equipment n Relatively expensive n Subjective n Limited to visible part of the Cx n CIN can be masked by HPV n Of most use in identifying area for biopsy n Better therefore than previous alternative of cone biopsy

Histology n The gold standard for diagnosis n Only as good as the sample received » (except for cone or LLETZ) n And still somewhat subjective n But accuracy is increased if stains for high risk HPV DNA is used

Natural History of CIN Progression 1  2  3  cancer is not inevitable Progression 1  2  3  cancer is not inevitable n CIN % spontaneously regress n CIN 3 – 50% regress or stay the same n Progression time varies » 6m to 16 years n But some will have invasive Ca when Pap smear reports only LGEA

HPV Subtyping n 90% of Ca Cx is associated with High Risk HPV »Subtypes 16,18,45,31,33,35,52,58 etc n Highly sensitive for the detection of HGEA n Does not require equipment or expertise n Equivocal results can occur n Of most use in the follow up of treated CIN n And those patients with persisting LGEA on Pap smear

Treatment Options for CIN n Observation » LGEA » Young women » Obvious HPV infection » Chronic LGEA with Low risk HPV subtype n Targeted destruction » Laser » Diathermy » Cryotherapy n Excision of the Squamocolumnar Junction » LETZ » Cone Biopsy n Hysterectomy

Follow up of CIN n 90 – 95% will be “cured” forever n Pap smears »Repeated until negative »12 monthly for 2 years n Colposcopy »Ideally at least once 6m after the procedure n HPV High Risk subtyping »Perform 12m and 24m after the procedure »High negative predictive value n Obstetric implications of treated CIN debatable

Current NH&MRC Guidelines n Repeat Pap once 12m after the first or if no tests for 5 years. Thereafter 2 yearly n Unsatisfactory Pap »Treat as required »Repeat in 3m »Send for colposcopy if 3 consecutive unsatisfactory n For LGEA »If <30 years repeat in 12 months »If >30 refer for colposcopy or repeat in 6m n For HGEA »Send for colposcopy

Prevention of CIN and Genital Warts n Polyvalent vaccines (types 6,11, 16 & 18) »Provide 90 – 100% protection from persistent infection, 16/18-related CIN2-3, adenoCa in situ and Ca Cx »Also protects against genital warts caused by the low risk HPV subtypes 6 & 11 n Therapeutic vaccines also under study n Optimal age for immunisation and need for boosters under evaluation n Male immunisation has started

Counselling a Patient with a Positive Pap Smear n This is not cancer »It is pre cancer »It is the whole point of doing Pap tests i.e. to detect and treat pre cancer so as to prevent it becoming cancer »Just like watching /removing “moles” of the skin »Not all pre cancer becomes cancer n It is a common condition »40 – 50% of ♀ not immunised at some time in their life »STD basis not helpful but may need to be addressed n The Pap test is not diagnostic »Only a well-directed biopsy can be used for Rx decisions

Any Questions or Comments? Please leave a note on the Welcome Page of this website